Combination Products Regulatory Considerations with FDA's Barr Weiner
Source: Drug Delivery Leader
From his roles and experiences in the combination products and combined use systems arena, John “Barr” Weiner offers perspectives on how to approach pre- and post-market activities with regulatory requirements and guidance in mind. Cross-functional coordination, integrated development, and primary mode of action (PMOA) designations are among the considerations Barr reminds organizations to implement thoughtfully as they work to advance combination products within a regulatory landscape.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.
Subscribe to Drug Delivery Leader
X
Subscribe to Drug Delivery Leader
This website uses cookies to ensure you get the best experience on our website. Learn more